Table 2.
Oncologic outcomes of patients undergoing radical cystectomy
| Robotic (n=36) | Open (n=29) | p value | |
|---|---|---|---|
| Median lymph nodes examined (IQR) | 17 (12-20) | 14 (10-20) | 0.43 |
| Lymph node involvement (%) | 0.86 | ||
| Positive | 8 (22) | 7 (24) | |
| Negative | 28 (78) | 22 (76) | |
| Lymphovascular invasion (%) | 0.52 | ||
| Yes | 19 (53) | 13 (45) | |
| No | 17 (47) | 16 (55) | |
| Cystectomy pathology (%) | 0.46 | ||
| pT0 | 5 (14) | 1 (3) | |
| pCIS/Ta/T1 | 10 (28) | 12 (41) | |
| pT2 | 4 (11) | 4 (14) | |
| pT3 | 11 (31) | 6 (21) | |
| pT4a | 6 (17) | 6(21) | |
| Cystectomy margin (%) | 1.00 | ||
| Positive | 2 (6) | 2 (7) | |
| Negative | 34 (94) | 27 (93) | |
| Ureteral margin (%) | 1.00 | ||
| Positive | 3 (8) | 2 (7) | |
| Negative | 33 (92) | 27 (93) | |
| Adjuvant chemotherapy (%) | 0.38 | ||
| Yes | 8 (22) | 4 (14) | |
| No | 28 (78) | 25 (86) | |
| Median follow-up, months (IQR) | 12.3 (7.5-20.4) | 12.2 (8.1-20.0) | 0.85 |
| 2-year recurrence-free survival (95% CI) | 67% (41-83) | 58% (29-79) | 0.80 |